Core Insights - Tempus AI (TEM) is on track to achieve a significant milestone in its 10th year, projecting a full-year adjusted EBITDA of $5 million, which represents an improvement of approximately $110 million over 2024 [1] - The company narrowed its adjusted EBITDA loss by $27.8 million year over year to negative $16.2 million, indicating effective cost management [1][10] Revenue and Profitability - First-quarter revenues surged by 75.4% year over year, driven by an 89% increase in Genomics, a 31% rise in Oncology testing, and a $63.5 million contribution from Hereditary testing [2] - Gross profit increased at an even higher rate of 99.8% year over year, nearly doubling the growth rate from the previous quarter, supported by gross margin expansion in Genomics and Data and services [2] Competitive Landscape - Compared to older peers like Guardant Health and Myriad Genetics, which are still facing significant annual losses, Tempus is experiencing rapid growth and margin improvements, positioning itself for a promising shift to profitability [3] - Guardant Health reported an adjusted EBITDA loss of $58.5 million for Q1 2025, while Myriad Genetics posted an adjusted EBITDA near breakeven [4][5] Stock Performance - Year to date, Tempus AI shares have increased by 71.8%, significantly outperforming the industry average growth of 22.9% [8][10] - The stock trades at a forward 12-month sales multiple of 7.36X, which is lower than its median of 28.64X but above the industry average of 6.03X [9]